Amyotrophic Lateral Sclerosis: A Focus on Disease Progression
Since amyotrophic lateral sclerosis (ALS) was discovered and described in 1869 as a neurodegenerative disease in which motor neuron death is induced, a wide range of biomarkers have been selected to identify therapeutic targets. ALS shares altered molecular pathways with other neurodegenerative dise...
Main Authors: | Ana C. Calvo, Raquel Manzano, Deise M. F. Mendonça, María J. Muñoz, Pilar Zaragoza, Rosario Osta |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2014-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2014/925101 |
Similar Items
-
MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis.
by: Janne M Toivonen, et al.
Published: (2014-01-01) -
Are Circulating Cytokines Reliable Biomarkers for Amyotrophic Lateral Sclerosis?
by: Laura Moreno-Martinez, et al.
Published: (2019-06-01) -
Decoding Amyotrophic Lateral Sclerosis: Discovery of Novel Disease-Related Biomarkers and Future Perspectives in Neurodegeneration
by: Ana Cristina Calvo, et al.
Published: (2014-01-01) -
Inflammatory and non-inflammatory monocytes as novel prognostic biomarkers of survival in SOD1G93A mouse model of Amyotrophic Lateral Sclerosis.
by: Samanta Gasco, et al.
Published: (2017-01-01) -
Circulating Cytokines Could Not Be Good Prognostic Biomarkers in a Mouse Model of Amyotrophic Lateral Sclerosis
by: Laura Moreno-Martínez, et al.
Published: (2019-04-01)